| 1. |
中华医学会感染病学分会肝衰竭与人工肝学组和中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].药品评价, 2007, 14(1):3-7.
|
| 2. |
Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system[J]. J Gastroenterol Hepatol, 2006, 21(10):1519-1524.
|
| 3. |
赵振刚, 韩涛, 高英堂, 等.乙型肝炎患者并发慢加急性肝衰竭诱因及转归分析289例[J].世界华人消化杂志, 2009, 17(31):3269-3272.
|
| 4. |
陈垦, 伍灵达, 崔淑兰.心源性肝硬化[J].临床荟萃, 1993, 8(17/18):782-784.
|
| 5. |
Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics:a phaseⅢ, randomized, double-blind, placebo-controlled study (QUEST study)[J]. Cardiovasc Drugs Ther, 2011, 25(Suppl 1):S33-S45.
|
| 6. |
Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20):2099-2112.
|
| 7. |
Kinugawa K, Ohtani T. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure[J]. Int Heart J, 2014, 55(3):264-267.
|
| 8. |
Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population[J]. J Cardiol, 2013, 61(1/2):169-174.
|
| 9. |
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2012, 367(25):2407-2418.
|
| 10. |
Plosker GL. Tolvaptan[J]. Drugs, 2010, 70(4):443-454.
|
